Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NNC0194 0499

Next Previous
Drug Profile

NNC0194 0499

Alternative Names: NN 9500; NN9499; NNC-0194-0499

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Drug withdrawal therapies; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Fibroblast growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Substance-related disorders
  • Phase I Non-alcoholic fatty liver disease; Type 1 diabetes mellitus
  • No development reported Obesity

Most Recent Events

  • 01 Jul 2025 Phase-I clinical trials in Type 1 diabetes mellitus (Combination therapy) in Germany (SC) (NCT07087795)
  • 01 Jul 2025 Phase-I clinical trials in Type 1 diabetes mellitus (Monotherapy) in Germany (SC) (NCT07087795)
  • 14 Mar 2025 Novo Nordisk completes a phase II trial in Non-alcoholic steatohepatitis (Combination therapy) in USA, Australia, Italy, Japan, South Korea, Poland, Singapore, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, India, Malaysia, Portugal, Puerto Rico, Russia, Spain, Taiwan, Turkey and United Kingdom (SC) (NCT05016882)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top